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Background: Elizabethkingia meningoseptica, formerly known as Chryseobacterium meningosepticum, is a non-motile, non-fastidious, catalase and oxidase-positive, aerobic, glucosenon-fermentative, Gram-negative bacillus that was first defined by Elizabeth O. King in 1959.
It has emerged as an opportunistic pathogen that has infected patients in extreme age groups
and immunocompromised individuals, especially in intensive care settings. There has been an
increased interest in this pathogen due to its increasing occurrence around the world, ubiquitous nature, and inherent capacity for antimicrobial resistance.
Methods: We describe an observational study at a tertiary care center in Karachi, Pakistan,
based on patients admitted between January 2013 and December 2018, with E. meningoseptica infections. All patients were confirmed to have a positive clinical culture specimen for E.
meningoseptica along with symptoms and signs consistent with infection. Data were collected on a structured proforma from the Hospital Information Management Systems.
Results: Sixteen patients with E. meningoseptica that met the criteria for infection were identified, 13 of whom required admission. Eight patients had bacteremia in addition to confirmed
E. meningoseptica infection. Two of the isolates were multi-drug resistant and only sensitive to
minocycline. Nine out of 13 patients that were admitted required intubation and mechanical
ventilation. The median length of hospital stay was 13 days, and five out of the 13 patients died
during the hospital stay.
Conclusion: This is the largest case series to date reporting E. meningoseptica infections and
highlights the importance of this organism as an emerging nosocomial pathogen.
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INTRODUCTION
Elizabethkingia meningoseptica, formerly known as Chryseobacterium meningosepticum, is a
non-motile, non-fastidious, catalase and oxidase-positive, aerobic, glucose-non-fermentative,
Gram-negative bacillus that was first defined by Elizabeth O. King in 1959 [1]. The Elizabethkingia genus has been noted due to the genetic makeup that facilitates a large degree of genetic
variability and subsequent antimicrobial resistance. This, combined with lack of literature reports on the wide distribution in nature and of adequate treatment regimens have led to high
mortality rates in hospital-settings, particularly in intensive care units (ICUs), since 2004 [2].
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E. meningoseptica is isolated most frequently from soil, saltwater, and freshwater and from dry and moist clinical environmental and equipment surfaces, intravenous lipid solutions, and municipal water supplies, including those adequately chlorinated [3]. Although nearly ubiquitous in nature, it is
an uncommon human pathogen. E. meningoseptica predominately causes outbreaks of meningitis in immunocompromised patients, particularly in premature newborns and infants in neonatal ICUs of developing countries [4]. The bacterium is a rare cause of nosocomial pneumonia, endocarditis,
and meningitis in immunocompromised adults. More recently, in the past few years, it has been found to cause soft tissue
infection and sepsis in immunocompetent adults [5].
In a study from Wisconsin, 48 cases of Elizabethkingia infection were reported during an outbreak, which resulted in
17 deaths in a 5-month period beginning in November 2015
[6]. Another case series showed that the yearly incidence of E.
meningoseptica bacteremia increased substantially from 2002
to 2006 (from 6.8–13.1 to 26.6–39.9 per 100,000 admissions;
P = 0.006) [7].
Moreover, Elizabethkingia, similar to its genetic relative chryseobacterium species, is inherently extensively drug resistant.
It is resistant to a broad spectrum of antibiotic classes, including macrolides, tetracyclines, linezolid, polymyxin group, chloramphenicol, aminoglycosides, and beta-lactam drugs [8]. Vancomycin, rifampicin, new fluoroquinolones, piperacillin-tazo
bactam, and minocycline are the current preferred empirical
choices for treating E. meningoseptica infections.
E. meningoseptica is an important emerging opportunistic
bacterium that primarily occurs in nosocomial settings. It is
unclear which treatment regimen is most effective and what
factors are associated with adverse outcomes. The aim of this
study is to describe the clinical features and outcomes of E.
meningoseptica infections in a tertiary care center in Karachi,
Pakistan.

MATERIALS AND METHODS
The study received an exemption from ethical approval from
the Aga Khan University Ethics Review Committee (ERC #20191786-4439) and requirement of informed consent was waived
due to retrospective nature of study. Data was anonymized
and no personal identifiers were collected.
This was an observational study of patients admitted between January 2013 and December 2018, with E. meningoseptica infections. All patients were confirmed to have a positive
clinical culture specimen for E. meningoseptica along with
2 https://www.accjournal.org

KEY MESSAGES
■E
 lizabethkingia meningoseptica is an opportunistic
pathogen infecting people in the extremes of age and
the immunocompromised, especially in intensive care
settings.
■W
 e are describing the largest case series to date reporting E. meningoseptica infections.
■O
 ur study found that Chryseobacterium meningosepticum is an emerging nosocomial pathogen causing mortality in patients requiring intensive care and outcomes
are better if isolates are susceptible to quinolones.

signs and symptoms consistent with infection. All patients
presumed to be colonized but not infected were excluded.
Data were collected on a structured proforma from the Hospital Information Management Systems. Identification and susceptibility of E. meningoseptica isolated from cultures were
performed by automated systems in accordance with Clinical
Laboratory Standards Institute recommendations. Identification of E. meningoseptica was determined by a Vitek 2 system
(bioMerieux, Marcy-l’Étoile, France).

Definitions
Infection was defined based on clinical presentation along
with patient-related factors and microbiological diagnosis. The
Center for disease control/National Healthcare Safety Network
definitions [9] for specific types of infections were used. A multidisciplinary team of doctors including infectious disease
consultants, pulmonologists, and intensivists was involved in
case identification and management. Patients were considered to be colonized if they had positive culture results for the
organism but no signs and symptoms to suggest active infection based on the primary physician evaluation and continued status of good health without treatment. Patients were
considered to have co-infection if a clinically significant true
pathogen was identified simultaneously from a culture specimen and the patient improved after corresponding treatment.
Patients were considered to have co-colonization if the pathogen isolated was a known contaminant or did not produce
signs and symptoms consistent with infection. Polymicrobial
infection was defined as the presence of another bacteria or
fungi in the same culture specimen. Multi-drug resistance was
defined as acquired non-susceptibility to at least one agent in
three or more antimicrobial categories [10]. Death was confirmed as all-cause mortality during hospitalization.

Acute and Critical Care 2021 July 26 [Epub ahead of print]

Umair A, et al. Elizabethkingia meningoseptica: an emerging pathogen

Statistical Analysis

admissions. The median age was 29 years for six males and
seven females, with ages ranging from 3 days to 83 years. The
most common comorbid conditions were diabetes (5/13) and
hypertension (5/13). The average Charlson’s comorbidity index was 3.3. Three patients had underlying malignancy, and
five patients had a history of repeated hospitalization. Eleven
patients were admitted to the ICU. Eight of 13 patients had
bacteremia with E. meningosepticum, and the most common
source of bacteremia was central line-associated bloodstream
infection in six patients. Among other sites of infection, one
had urinary tract infection, two had meningitis, two had pneumonia, and one had infective endocarditis. Nine patients had
mono-microbial growth, whereas four had polymicrobial growth
in culture. Of 13 patients, eight required a Foley catheter and
nine required a central venous catheter, endotracheal intubation, and mechanical ventilation. The clinical characteristics

Data were analyzed using IBM SPSS ver. 19 (IBM Corp., Armonk, NY, USA). Descriptive analysis was performed for demographic features with median and interquartile range values reported for quantitative variables such as age and length
of hospital stay, and frequency (percentage) were reported for
qualitative variables such as sex, comorbid conditions, mortality, and complications. A P-value ≤ 0.05 was considered statistically significant. Data were kept confidential, and no personal identifiers were used.

RESULTS
Sixteen patients with E. meningoseptica infections were identified between 2013 and 2018, 13 of whom required hospital
admission, constituting an infection rate of 2.9 per 100,000

Table 1. Summary of patients with Elizabethkingia meningoseptica infections
No.

Age/sex

Associated disease

1

Term baby at the 2nd day of None
life

2

Site of infection
Meningitis

Type of strain
Drug sensitive

Treatment

Outcome

Ciprofloxacin

Recovered

Preterm 33-week-baby girl Respiratory distress synBloodstream infection (um- Drug sensitive
brought to NICU at the 3rd drome, bilateral intravenbilical vein catheterization)
day of life
tricular hemorrhage

Minocycline

Recovered

3

5 day/F

Subglottic stenosis

Bloodstream infection
(source unclear)

Drug sensitive

Levofloxacin

Recovered

4

19 yr/M

SLE, CKD

Central line-associated
bloodstream infection

Drug sensitive

Cotrimoxazole

Recovered

5

22 yr/M

Status post-RTA with anoxic Central line-associated
brain injury, craniotomy,
bloodstream infection
tracheostomy, liver injury

Multi-drug resis- Minocycline
tant

Recovered

6

25 yr/F

Pregnancy induced hyper- Urinary tract infection
tension, post-partum hemorrhage

Drug sensitive

Cefixime

Recovered

7

29 yr/M

Dengue hemorrhagic fever

Central line-associated
Bloodstream infection

Drug sensitive

Meropenem

Recovered

8

41 yr/F

DM, HTN, APLA syndrome,
left MCA stroke

Bloodstream infection
(infective endocarditis)

Multi-drug resis- Minocycline
tant

9

54 yr/F

DM, HTN, esophageal carci- Hospital-acquired pneumo- Drug sensitive
noma
nia

Levofloxacin

Death

10

58 yr/M

DM, HTN, IHD

Cotrimoxazole

Death

11

65 yr/F

DM, CLD, glioblastoma grade Central line-associated
IV
bloodstream infection

Drug sensitive

Minocycline

Death

12

76 yr/F

DM, HTN, IHD, CKD

Meningitis

Drug sensitive

Levofloxacin+
cotrimoxazole

Recovered

13

86 yr/M

DM, HTN, IHD

Central line-associated
bloodstream infection

Drug sensitive

Levofloxacin

Death

Hospital-acquired pneumo- Drug resistant
nia

Death

NICU: neonatal intensive care unit; SLE: systemic lupus erythematosus; CKD: chronic kidney disease; RTA: road traffic accident; DM: diabetes mellitus;
HTN: hypertension; APLA: anti-phospholipid antibody; MCA: middle cerebral artery; IHD: ischemic heart disease; CLD: chronic liver disease.
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Figure 1. Antibiotic susceptibility of Elizabethkingia meningoseptica isolates.
Table 2. Summary of studies reporting Elizabethkingia infections and outcomes
Study

Sample size

Clinical diagnosis

Risk factor

Treatment

Outcome

Khan et al. [11] (2015)

4

Empyema, peritonitis, en- CKD, valvular heart disease, Cotrimoxazole-sensitive iso- 3 Survived;
docarditis, intra-abdomi- ruptured ectopic preglates
1 died
nal sepsis
nancy

Arbune et al. [12] (2018)

1

Meningitis

Preterm baby

Piperacillin, tazobactam, and Survived
Rifampin

Celik et al. [13] (2019)

3

Ventilator-associated
pneumonia

Preterm infants

One baby treated with cefo- All survived
perazone-sulbactam and 2
babies treated with ciprofloxacin

Hamza et al. [14] (2018)

4

Central line-associated
bloodstream infection
and hospital-acquired
pneumonia

Pediatric patients requiring Treatment details not avail- All survived
intensive care
able

Sahu et al. [15] (2019)

1

Ventilator-associated
pneumonia

Five-month-old baby with Cotrimoxazole in combinacongenital heart disease tion with ciprofloxacin

Died

Raghavan et al. [16]
(2017)

1

Urinary tract infection

Congestive heart failure

Minocycline

Survived

Treatment details and susceptibility patterns not
available

138 Survived;
89 dieda

Dziuban et al. [17]
(2018)

283 Pediatric cases Spine was the most com- Infants
from 28 countries
mon site of infection.
(1944–2017)

CKD: chronic kidney disease.
a
The outcome was unknown in 56 patients.

of all 13 patients are summarized in Table 1. E. meningosepticum was sensitive to quinolones in five of 13 isolates. Two of
the E. meningosepticum isolates were multi- drug resistant
with sensitivity only to minocycline, which was the drug used
for definitive treatment. The susceptibility pattern of all isolates is summarized in Figure 1. Five of 13 patients were treated with a quinolone, four with cotrimoxazole, and four with
minocycline. However, culture appropriate antibiotics were
not initiated in two patients. The most common co-infection
was with multi-drug resistant Acinetobacter (n = 2) or Pseudo4 https://www.accjournal.org

monas aeruginosa (n = 2). Five of 13 patients died, two cases
were referred for palliative care in view of advanced underlying malignancy, and the median length of hospital stay was 13
days. All five patients who died had a history of repeat hospitalization and significant comorbidities. All five of these patients were mechanically ventilated and underwent invasive
catheterization. E. meningoseptica was isolated from the blood
of three patients and from tracheal aspirate in one patient who
had undergone esophagectomy, thoracotomy, and tracheostomy. Death could be attributed to E. meningoseptica infecAcute and Critical Care 2021 July 26 [Epub ahead of print]
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tion in two of five patients. One patient had repeated isolation
of the organism from blood cultures due to infective endocarditis, and the other had nosocomial pneumonia after prolonged
hospitalization.

ORCID

DISCUSSION

AUTHOR CONTRIBUTIONS

Our study identified and analyzed Elizabeth meningoseptica
infections in patients with underlying comorbidities, particularly in patients that required frequent hospitalizations. While
many isolated case reports and series have been reported [1116], only a few [17] have included more than four Elizabethkingia cases (Table 2). There are no reports on Elizabethkingia
cases from Pakistan. Our study identified 16 patients in the
last six years with Elizabethkingia meningosepticum infections. Unlike other case series with predominantly neonatal
cases [17], our patients had a median age of 29 years. Similar
to other case reports, the infections were urinary tract infection and meningitis [11,16]. The outcomes have been variable,
with significant mortality among neonates [17]. However, patients with isolates susceptible to quinolones and treated with
Ciprofloxacin had better survival outcomes [14]. This result is
similar to patients that of who were treated with a quinolone
in our study.
E. meningosepticum is resistant to most commonly used
antimicrobials; therefore, options for treatment are limited.
Most studies have established that clinical isolates are resistant to aminoglycosides and beta lactams, with notable exception of piperacillin-tazobactam, and show sensitivities to
fluroquinolones and tetracyclines [15]. These patterns were
consistent with the results of this study.
This study is a single-center case series with several inherent limitations such as the small sample size and unavailability of molecular testing and minimum inhibitory concentration data on all isolates. However, this study is the largest to
date and the first from Pakistan, to report clinical features and
treatment outcomes of E. meningoseptica infections. Moreover, it offers insight into the sensitivity pattern of this organism in our region. E. meningosepticum is an emerging nosocomial pathogen that causes mortality in patients requiring
intensive care.
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